<Header>
<FileStats>
    <FileName>20241231_10-Q-A_edgar_data_1604950_0001193125-24-287051.txt</FileName>
    <GrossFileSize>319275</GrossFileSize>
    <NetFileSize>7948</NetFileSize>
    <NonText_DocumentType_Chars>131924</NonText_DocumentType_Chars>
    <HTML_Chars>57933</HTML_Chars>
    <XBRL_Chars>61394</XBRL_Chars>
    <XML_Chars>55045</XML_Chars>
    <N_Exhibits>7</N_Exhibits>
</FileStats>
<SEC-Header>
0001193125-24-287051.hdr.sgml : 20241231
<ACCEPTANCE-DATETIME>20241231060400
ACCESSION NUMBER:		0001193125-24-287051
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241231
DATE AS OF CHANGE:		20241231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			scPharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001604950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				465184075
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38293
		FILM NUMBER:		241591070

	BUSINESS ADDRESS:	
		STREET 1:		25 BURLINGTON MALL ROAD, SUITE 203
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803
		BUSINESS PHONE:		617-517-0730

	MAIL ADDRESS:	
		STREET 1:		25 BURLINGTON MALL ROAD, SUITE 203
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803

</SEC-Header>
</Header>

 0001193125-24-287051.txt : 20241231

10-Q/A
 1
 d917394d10qa.htm
 10-Q/A

10-Q/A 

UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION 

 Washington, D.C. 20549 

Form 

Amendment No. 1 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the quarterly period ended 

 OR 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

 For the transition period from 

to 

Commission file number: 

(Exact name of registrant as specified in its charter) 

(State or other jurisdiction of

 incorporation or organization)

(I.R.S. Employer

 Identification No.)

, 

, 

(Address of principal executive office)

(Zip Code)

 Registrant s telephone number, including area code: ) 

N/A 

 (Former name, former address and former fiscal year, if changed since last report) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading

 Symbol(s)

Name of each exchange

 on which registered

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. No 
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). No 
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
 filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2
 of the Exchange Act. 

Large accelerated filer 

Accelerated filer 

Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
 of the Exchange Act). Yes No 
 As of November 12, 2024, the Registrant had common shares, 0.0001 par value per share, outstanding. 

PART II - OTHER INFORMATION 

 Item 5. Other Information 

 (c) Insider Trading Arrangements and Policies. 
 On August 20, 2024, John H. Tucker, the Company s President and Chief Executive Officer, entered into a sell-to-cover

 instruction letter (the Tucker Instruction Letter that provides for sales of only such number of shares of the Company s common stock, 0.0001 par value (the Common Stock ), as are necessary to satisfy the applicable tax withholding obligations arising exclusively from the vesting or settlement of restricted stock units RSUs granted to Mr. Tucker under the Company s 2017 Stock Option and Incentive Plan, or any successor plan. The Tucker Instruction Letter is a Rule 10b5-1
 trading arrangement as defined in Item 408(a) of Regulation S-K
 and is intended to satisfy the affirmative defense of Rule 10b5-1(c).
 
 The Tucker Instruction Letter will remain in effect so long as taxes are required to be paid upon the vesting or settlement of RSUs awarded or to be awarded, unless the Tucker Instruction Letter is earlier terminated. The total number of shares of Common Stock that may be sold pursuant to the Tucker Instruction Letter is not determinable. 
 On August 21, 2024, Rachael Nokes, the Company s Chief Financial Officer, entered into a sell-to-cover

 instruction letter (the Nokes Instruction Letter that provides for sales of only such number of shares of the Company s Common Stock as are necessary to satisfy the applicable tax withholding obligations arising exclusively from the vesting or settlement of RSUs granted to Ms. Nokes under the Company s 2017 Stock Option and Incentive Plan, or any successor plan. The Nokes Instruction Letter is a Rule 10b5-1
 trading arrangement as defined in Item 408(a) of Regulation S-K
 and is intended to satisfy the affirmative defense of Rule 10b5-1(c).
 
 The Nokes Instruction Letter will remain in effect so long as taxes are required to be paid upon the vesting or settlement of RSUs awarded or to be awarded, unless the Nokes Instruction Letter is earlier terminated. The total number of shares of Common Stock that may be sold pursuant to the Nokes Instruction Letter is not determinable. 
 Other than as disclosed above, during the three months ended September 30, 2024, no director or officer of the Company or a Rule 10b5-1
 trading arrangement or non-Rule
 10b5-1
 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits 

 EXHIBIT INDEX 

Exhibit
 Number

Description

31.1 
 
 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

31.2 
 
 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 

101 
 
 Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, Financial Statements of this Quarterly Report on Form 10-Q.

104 
 
 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101 ). 

Filed herewith. 

SIGNATURES 

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

SCPHARMACEUTICALS INC.

Date: December 31, 2024 

By: 
 
 /s/ Rachael Nokes

Rachael Nokes 

Chief Financial Officer
 (Principal Financial Officer)

<EX-31.1>
 2
 d917394dex311.htm
 EX-31.1

EX-31.1 

Exhibit 31.1 
 CERTIFICATION I, John H. Tucker, certify that:

1. 
 I have reviewed this Amendment No. 1 to the Quarterly Report on Form
 10-Q/A of scPharmaceuticals Inc.; and 

2. 
 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

Date: December 31, 2024 
 
 /s/ John H. Tucker 
 
 John H. Tucker 
 
 President and Chief Executive Officer 
 (Principal Executive Officer) 

</EX-31.1>

<EX-31.2>
 3
 d917394dex312.htm
 EX-31.2

EX-31.2 

Exhibit 31.2 
 CERTIFICATION I, Rachael Nokes, certify that:

1. 
 I have reviewed this Amendment No. 1 to the Quarterly Report on Form
 10-Q/A of scPharmaceuticals Inc.; and 

2. 
 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

Date: December 31, 2024 
 
 /s/ Rachael Nokes 
 
 Rachael Nokes Chief Financial Officer 
 (Principal Financial Officer) 

</EX-31.2>

<EX-101.SCH>
 4
 scph-20240930.xsd
 XBRL TAXONOMY EXTENSION SCHEMA

</EX-101.CAL>

<EX-101.DEF>
 6
 scph-20240930_def.xml
 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

</EX-101.DEF>

<EX-101.LAB>
 7
 scph-20240930_lab.xml
 XBRL TAXONOMY EXTENSION LABEL LINKBASE

</EX-101.LAB>

<EX-101.PRE>
 8
 scph-20240930_pre.xml
 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

</EX-101.PRE>

